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Abstract: The resolution of arterial thrombi is critically dependent on the endogenous fibrinolytic
system. Using well-established and complementary whole blood models, we investigated the
endogenous fibrinolytic potential of the tissue-type plasminogen activator (tPA) and the intra-
thrombus distribution of fibrinolytic proteins, formed ex vivo under shear. tPA was present at
physiologically relevant concentrations and fibrinolysis was monitored using an FITC-labelled
fibrinogen tracer. Thrombi were formed from anticoagulated blood using a Chandler Loop and from
non-anticoagulated blood perfused over specially-prepared porcine aorta strips under low (212 s−1)
and high shear (1690 s−1) conditions in a Badimon Chamber. Plasminogen, tPA and plasminogen
activator inhibitor-1 (PAI-1) concentrations were measured by ELISA. The tPA–PAI-1 complex was
abundant in Chandler model thrombi serum. In contrast, free tPA was evident in the head of thrombi
and correlated with fibrinolytic activity. Badimon thrombi formed under high shear conditions were
more resistant to fibrinolysis than those formed at low shear. Plasminogen and tPA concentrations
were elevated in thrombi formed at low shear, while PAI-1 concentrations were augmented at high
shear rates. In conclusion, tPA primarily localises to the thrombus head in a free and active form.
Thrombi formed at high shear incorporate less tPA and plasminogen and increased PAI-1, thereby
enhancing resistance to degradation.
Keywords: plasminogen activator inhibitor-1; fibrinolysis; tissue plasminogen activator; thrombi; shear
1. Introduction
Fibrinolysis is responsible for counterbalancing thrombus formation, promoting
thrombus dissolution and facilitating wound healing. Plasmin is the key proteolytic
enzyme responsible for degradation of fibrin and is formed by the cleavage of the zymogen
form, plasminogen, at Arg561-Val562 [1,2]. The two principal physiological plasminogen
activators are tissue-type plasminogen activator (tPA) and urokinase-type plasminogen
activator (uPA). Under normal conditions, the circulating concentration of tPA is low but
local concentrations rise markedly following release from vascular endothelial cells in
response to stimuli including shear stress, fibrin deposition, thrombin and bradykinin [3–6]
promoting fibrinolysis and thrombus resolution [7]. The rate at which fibrinolysis proceeds
is dependent on several factors and the process is normally tightly regulated by inhibitors
of these proteases. The serpin, plasminogen activator inhibitor-1 (PAI-1), is the principal
inhibitor of tPA and uPA, rapidly inactivating them by forming a 1:1 complex which is then
cleared from the circulation via the hepatic system. Whilst platelets are the primary source
of circulating PAI-1 [8,9], releasing and retaining functional PAI-1 on their membrane [10],
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it is also synthesised by endothelial cells [11], adipocytes [12–14], hepatocytes [15] and
cardiomyocytes [16] and the concentration of circulating PAI-1 increases in response to
several inflammatory cytokines [17–22].
The shear conditions in which thrombi form greatly impacts their structure and
composition [23,24], both of which are important factors in determining how resistant
a given thrombus is to fibrinolytic degradation [25]. Strain tends to align fibres on the
surface of the thrombus in the direction of flow, whereas interior fibres have a more random
and porous orientation [26,27]. Fibrin networks consisting of thin fibres are more tightly
packed [28] and these dense clots are more resistant to fibrinolytic degradation [29]. In
addition to the composition of fibrin, thrombi formed under high shear conditions contain
high numbers of platelets, while those forming under lower shear conditions are more
fibrin- and erythrocyte-rich [23]. Platelet-rich thrombi are more resistant to lysis than
erythrocyte-rich thrombi [30], which likely explains the failure of some vessels to recanalize
after thrombolytic therapy [31].
We have previously demonstrated a concentration dependent effect of tPA-mediated
fibrinolysis in overcoming thrombin activatable fibrinolysis inhibitor (TAFI) inhibition in
the Chandler model [32]. In those studies, tPA was added at a relatively high concentration
(1 µg/mL) after thrombus formation [32]. In the present study, we aimed to characterise:
(i) the distribution of tPA and other important fibrinolytic proteins in thrombi and (ii) the
downstream implications in terms of fibrinolysis, when thrombi are formed in the presence
of physiological concentrations of tPA under flow conditions equivalent to those encoun-
tered in the venous and arterial circulations. We investigated the impact of shear rate
on fibrinolysis in thrombi formed from non-anticoagulated blood in an ex vivo model of
coronary arterial injury.
2. Results
2.1. Fibrin Formation and Fibrinolysis Occur Simultaneously during Thrombus Formation
The endothelium is the major source of tPA during inflammatory insult to the vascula-
ture [33]. To mimic this situation, we formed Chandler model thrombi under rotation in
the presence of exogenous tPA (20 or 40 ng/mL). Incorporation of tPA during thrombus
formation resulted in ongoing thrombus formation and dissolution. We characterised the
optimal time for thrombus formation to be 30 min, as after this point, substantial fluo-
rescence release was detected in the Chandler loop serum which is indicative of ongoing
fibrinolysis (Figure S1). Using this optimised time for thrombus formation we determined
that lysis was significantly enhanced upon incorporation of tPA compared to the absence of
tPA (Figure 1A, p < 0.001). Consistent with this, D-dimer concentrations in the bathing fluid
were increased—indicative of ongoing fibrinolysis (Figure 1B)—and strongly correlated
with fluorescence release (r = 0.98) (Figure 1C).
2.2. Incorporated tPA Protects Thrombi against Inhibition by PAI-1
To establish the degree to which tPA is incorporated into thrombi, we quantified tPA in
thrombus extracts of Chandler model thrombi and the residual serum. Negligible quantities
of tPA were detected in thrombus extracts and serum (0.05 ± 0.01 and 3.25 ± 0.56 ng,
respectively) in the absence of exogenous tPA (Figure 2A). Limited detection of tPA in this
circumstance is not surprising, given the lack of endothelium in this system. Inclusion
of both 20 and 40 ng/mL tPA during thrombus formation augmented the levels in the
thrombus extract (5.28 ± 0.83, p < 0.01, and 9.84 ± 1.83 ng, p < 0.001, respectively) and
serum (14.78 ± 0.20 and 24.0 ± 0.84 ng, respectively, p < 0.001 for both) indicating that
approximately a quarter was incorporated into the thrombus. The PAI-1 contents in thrombi
and serum were unaltered by incorporation of tPA (Figure 2B) and were always in excess
of tPA.
The association of PAI-1 and tPA was further examined in the thrombus extract and
serum by zymography (Figure 2C). In serum, tPA was in complex with PAI-1 and other
inhibitors. In marked contrast, in the thrombus extract, tPA was evident in a free uncom-
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plexed form (Figure 2C), suggesting functional tPA persisted within the microenvironment
of the thrombi despite high levels of PAI-1 (Figure 2B).
Figure 1. Dose-dependent thrombolysis with endogenous levels of tPA. Whole-blood model thrombi containing FITC-
fibrinogen were formed by rotation for 30 min in the presence or absence of 20 or 40 ng/mL added tissue-type plasminogen
activator (tPA). (A) Fibrinolysis was measured as relative fluorescence release (RFU) over 4 h in the bathing fluid. (B) D-dimer
levels were measured in the bathing fluid and (C) correlated with FITC results (R = 0.96). Data shown are mean ± SEM,
n ≥ 3. *** p < 0.001 vs. no tPA.
2.3. Fibrinolytic Activity Is Primarily Concentrated in the “Head” of Thrombus
Thrombi formed under flow in the Chandler loop show similar morphology to human
thrombi formed in vivo [23], comprising of a dense head, rich with platelet, erythrocytes,
leucocytes and fibrin, and with a tail region comprised mainly of fibrin [23]. We examined
the distribution of tPA in the thrombi. Lysis was increased in the head of the thrombus,
both in the absence and presence of exogenous tPA (Figure 3A, p < 0.001). Increasing
concentrations of endogenous tPA augmented the levels within thrombi which were
localised primarily within the head (Figure 3B). In contrast, PAI-1 levels remained constant
despite differences in tPA concentrations within the thrombus, suggesting there was no
substantial increase in tPA–PAI-1 complex levels (Figure 3C). Similarly, plasminogen
concentrated in the thrombus head and remained constant (Figure 3D). Free tPA was
detected in the thrombus head by zymography, suggesting it was protected from inhibition
by PAI-1 (Figure 3E).
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Figure 2. tPA incorporated into thrombi is protected from PAI-1 inhibition. Chandler model thrombi were formed and the
levels of (A) tPA, and (B) plasminogen activator inhibitor-1(PAI-1) in serum and thrombus extracts were measured by ELISA.
(C) Detection of tPA by zymography showing tPA and tPA–PAI-1 in the serum and thrombus extract after incorporation 0,
20 or 40 ng/mL tPA. Data shown are mean ± SEM (n = 4). ** p < 0.01, *** p < 0.001 vs. no tPA, a p < 0.05, c p < 0.001.
2.4. Shear Rate Influences the Fibrinolytic Protein Content of Thrombi and Impedes Fibrinolysis at
High Shear
To allow us to investigate the impact of flow conditions on fibrinolytic activity, we
next utilised a model that permitted us to study thrombus formation in non-anticoagulated
whole blood under well-defined low and high shear rates. Fibrinolysis in the absence of
exogenous tPA proceeded more efficiently at low shear compared to high shear (Figure 4A).
Inclusion of tPA (20 and 50 ng/mL) to thrombi formed at high shear had little impact on
the rate of lysis (Figure 4B). In contrast, lysis proceeded faster (4.8-fold increase, p < 0.001)
in thrombi formed at low shear (Figure 4B). Consistent with the enhanced fluorescence
release, D-dimer concentrations rose more quickly and to a higher level at low shear for
both tPA concentrations, indicating a faster rate of clot dissolution. Interestingly, despite
no detectable differences in the rate of fibrinolysis after incorporation of the different tPA
concentrations, a concentration dependent effect on D-dimer was observed under both low
and high shear conditions (Figure 4C,D).
The concentrations of tPA, PAI-1 and plasminogen were quantified in the bathing
fluid and the Badimon chamber effluent. A concentration dependent increase in tPA was
evident in the chamber effluent (Figure 5A). Basal levels were 0.2 ± 0.05 µg, increasing to
0.59 ± 0.07 and 1.97 ± 0.16 µg tPA after addition of 20 and 50 ng/mL tPA, respectively
(Figure 5A). Similar PAI-1 and plasminogen concentrations were detected in the effluent at
all tPA concentrations (Figure 5B,C).
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Figure 3. Incorporated tPA increased in the thrombus head. (A) Fibrinolysis was measured as fluorescence released in
the bathing fluid from heads and tails in the absence or presence of 20 or 40 ng/mL of incorporated tPA. Inset shows the
fluorescence released at 0 ng/mL of tPA on a smaller scale. (B) tPA, (C) PAI-1 and (D) plasminogen antigen concentrations
were measured by ELISA in extracts of heads and tails. (E) Detection of tPA by zymography showing tPA and tPA–PAI-1 in
extract of thrombus head and tail sections formed with incorporation of 0, 20 or 40 ng/mL tPA. Data shown are mean ± SEM
(n = 3). *** p < 0.001 vs. no tPA.
Figure 4. Fibrinolysis under high and low shear conditions. Whole blood thrombi were formed in Badimon chambers on
a thrombogenic surface under low (212 s−1) and high (1690 s−1) shear rates. Fibrinolysis was measured as fluorescence
release in the bathing fluid over time. Thrombi formed in the (A) absence or (B) with the incorporation of tPA at 20 or
40 ng/mL (B). D-dimer levels were measured at (C) high and (D) low shear rates. Data shown are mean ± SEM (n = 7).
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Figure 5. Thrombi formed at low shear have higher levels of tPA and plasminogen. Whole blood thrombi were formed in
Badimon chambers on a thrombogenic surface under low (212 s−1) and high (1690 s−1) shear rates. Levels of tPA, PAI-1
and plasminogen antigen were measured by ELISA in the effluent (A–C, respectively), * p < 0.05, *** p < 0.001 vs. no tPA,
c p < 0.001 vs. 20 ng/mL tPA and the thrombus bathing fluid (D–F, respectively), ** p < 0.01, *** p < 0.001 vs high shear.
Data shown are mean ± SEM (n = 7).
Negligible tPA was detected in the thrombus bathing fluid in the absence of exogenous
protein (high shear 0.02 ± 0.03 ng, low shear 0.05 ± 0.01 ng) (Figure 5D). The addition of
20 ng/mL tPA increased levels in the bathing fluid by around 6.6- and 8.5-fold at low and
high shear, respectively (Figure 5D). At low shear, tPA increased 2.8-fold in the bathing fluid
in the presence of exogenous tPA, whereas at high shear this effect was less pronounced.
These data suggest that incorporation of tPA into the thrombi is augmented under low
shear conditions. PAI-1 concentration in the bathing fluid was augmented at high shear
compared to low shear (Figure 5E). Inclusion of tPA at 20 or 50 ng/mL did not alter the
PAI-1 concentration in the bathing fluid at low or high shear but was unaltered by the
addition of tPA (Figure 5E). Interestingly, plasminogen levels in the bathing fluid were
elevated with increasing tPA incorporation and at low shear (Figure 5F). Together these
data suggest that high shear attenuates fibrinolysis by limiting the incorporation of tPA
and plasminogen into thrombus, while increasing PAI-1 content.
3. Discussion
The impacts of flow on platelet deposition, thrombus formation and fibrin structure
are well established. The relationship between flow and fibrinolysis is less clear due to the
complexity and limited availability of models. Our laboratories have been instrumental
in investigating fibrinolysis of thrombi formed in the presence of physiologically-relevant
levels of tPA and under a variety of continuous flow conditions [7,34–38]. Here, we utilised
two complementary ex vivo models to investigate fibrinolysis with endogenous levels
of tPA. Accumulation of tPA and plasminogen was observed in the head of Chandler
model thrombi, directly aligning with localisation of fibrinolytic activity. Within the
microenvironment of thrombi, tPA appeared protected from inhibition by PAI-1, whereas,
in serum it was found in complex with its inhibitor. The striking abundance of tPA in
the head of the thrombus was surprising considering this region is largely comprised of
platelets and leukocytes, while the thrombus tail is fibrin-rich nature [23]. Previously, we
demonstrated that endogenous thrombus lysis is largely mediated by uPA in the head
Int. J. Mol. Sci. 2021, 22, 2115 7 of 13
of thrombi, with a modest contribution from tPA [39,40]. The origin of this uPA activity
is polymorphonuclear cells that accrue in this region under flow [39,40]. Here, tPA was
included during thrombus formation, at physiologically-relevant levels.
Using an ex vivo model of vascular injury, we demonstrated—for the first time—the
direct impact of shear conditions on the localisation of fibrinolytic proteins and the down-
stream impact on lysis of thrombi formed from native whole blood, again in the presence
of physiologically-relevant levels of tPA.
Our previous work has shown that Chandler model thrombi accurately mimic human
arterial thrombi, consisting of platelet-rich head and fibrin-rich tail [23]. A recent study
examining arterial thrombi obtained after thrombectomy by scanning electron microscopy,
indicated that platelets accounted for 31% of the thrombus volume, whilst fibrin accounted
for 41% [41]. Conversely, venous thrombi are primarily composed of red blood cells and
fibrin, with platelets accounting for only 0.4% [41]. Platelets are the major pool of circulating
PAI-1 [8,9] and we have recently shown that the stimulated platelet membrane retains
functional PAI-1 [10]. Conversely, we have shown that platelets bind plasminogen via both
fibrin-dependent and independent mechanisms [38,42]. We identified the presence of the
plasminogen receptor, Plg-RKT, on the surface of platelets, which is augmented following
stimulation and acts as a binding partner for both plasminogen and tPA [42]. These data
imply that platelets function in both profibrinolytic and antifibrinolytic pathways within
the microenvironment of the thrombus. The balance of these functions may relate to their
positioning relative to the vessel wall, activation status and shear stress.
Thrombi formed ex vivo in the Badimon Chamber model form sequentially, at low
shear (approximately 212 s−1) and subsequently high shear (approximately 1690 s−1),
permitting direct comparison of thrombi formed from the same native blood sample. In
addition to allowing the effect of different shear conditions to be examined, this model has
several strengths, including that thrombus formation occurs as native blood and flows over
a pathophysiologically relevant thrombogenic surface [7]. Thrombi formed at high shear
were more resistant to fibrinolysis than those formed at low shear, likely due to higher
PAI-1 and lower tPA and plasminogen levels within these thrombi. The high PAI-1 levels
in the thrombi formed under high shear most likely reflect increased platelet deposition,
consistent with previous observation of high platelets in arterial thrombi [23,34,43–45].
D-dimer is commonly used as a clinical marker of increased fibrinolytic activity. An
exceptionally strong correlation between fluorescence release and the D-dimer levels was
observed during lysis of thrombi formed in a Chandler Loop. During lysis of the Badimon
Chamber thrombi, there was a difference in fluorescence release at high and low shear rates
which was reflected in the D-dimer concentrations. However, the sensitivity of the FITC-
fibrinogen tracer was not sufficient to detect changes in lysis at different tPA concentrations.
This most likely reflects the variations in these flow models, with the Chandler Loop being
a closed system, and the Badimon Chamber utilising a continuous flow of whole blood
and replenishment of plasma factors. In future studies utilising continuous flow, it may be
necessary to increase the ratio of the tracer relative to plasma fibrinogen to augment the
sensitivity of the system.
Thrombi formed in the Badimon chamber are comprised of platelet aggregates on the
thrombogenic surface and an associated fibrin layer [46], with increased fibrin deposition at
low shear [7]. Application of shear forces or mechanical stress is associated with alignment
of fibrin fibres in the direction of flow [26,27,47,48], which can alter lateral aggregation
and protofibril extension [49]. As a result, thrombi formed in different locale within the
body have varying degrees of fibre alignment [50]. Even within a thrombus, fibrin fibre
alignment is not uniform, with those fibres on the outer edge of thrombi being—exposed to
shear stress—aligning with flow, whereas interior fibres reveal a random orientation [27].
Shear impacts both on the structure of fibrin and on its ability to function as a cofactor in
tPA-mediated plasminogen activation [28]. The amplified resistance of thrombi formed
under high shear conditions in the Badimon Chamber may reflect changes in the structure
of the fibrin, with a subsequent deacceleration of plasminogen activation. Combined
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with high PAI-1 levels, this appears to contribute to an enhanced thrombus stability. A
recent microfluidic model, which was developed to study the impact of thrombolytic drugs
in vitro, demonstrated that thrombi formed at high shear are refractory to fibrinolytic
degradation at pharmacological concentrations of tPA [51].
Elegant in vivo models of thrombus formation reveal that thrombi have a hierarchical
structure, consisting of a dense core of highly activated platelets surrounded by a shell of
less activated platelets [52,53]. This concentrated platelet core impedes solute transport
from plasma implying that the contents of this area are less susceptible to convective
removal [54]. This suggests the intrathrombus content of fibrinolytic proteins may be
crucial in governing thrombus resolution. Here, we observed that tPA within thrombi was
protected from inhibition despite high levels of its principal inhibitor, PAI-1. Binding of
tPA and the downstream enzyme plasmin to a surface, either cellular or fibrin, confers
protection against inhibition by PAI-1 or α2 antiplasmin, respectively. In line with these
observations, we also determined the presence of free tPA in thrombi using zymography,
whereas tPA in the serum was in complex with PAI-1. These data indicate that despite
favourable kinetics, it is the local milieu that determines the fate of an interaction.
Our laboratory was the first to define a model in which to study fibrinolysis under
flow [38]. Using this parallel plate assay combined with high resolution confocal mi-
croscopy, we were able to visualise the delicate balance between fibrin formation and
dissolution in these thrombi [38]. These observations are reflected in the Chandler model
thrombus system, as enhanced fluorescence release, indicative of lysis, was observed in
the serum with increasing formation time of the thrombi. This highlights the dynamic
nature of thrombus formation with ongoing fibrinolysis, alongside coagulation, with the
degree of fibrin deposition dictated by the dominant system. In our previous study, we
observed a pool of plasminogen within the core of thrombus that was directly associated
with the platelet membrane [38]. These results are emulated here, with the prevalence of
plasminogen and tPA within the head of Chandler thrombi, which is rich in platelets and
leukocytes. Whilst it was previously believed that fibrin was the main surface driving
plasminogen activation, a plethora of data now underscore the importance of cellular
surfaces in the regulation of fibrinolysis [42,55–58].
The data presented here clearly demonstrate that fibrinolytic proteins are not uni-
formly distributed throughout thrombi and are also impacted by shear stress. Flow based
assays recapitulate the hemodynamic conditions required for platelet deposition and fibrin
formation, subjecting the thrombus to the convective forces that influence local protein
concentrations [59]. One limitation of the current study is that fibrinolysis is not directly
studied under flow. Study under flow conditions is complicated by the convective removal
and dilution of proteins of interest meaning that there can be a reduction in sensitivity
compared to traditional static assays. This has confounded the ability to develop models in
which to study fibrinolysis. Recent advances in microscopy and biorheological approaches
have pushed the boundaries of fibrinolytic research, permitting visualisation of fibrinolysis
in flow models [38,51,59] and in vivo [57,58]. Microfluidic models incorporating sup-
raphysiological levels of tPA have utility in testing thrombolytic drugs [51] and can be
applied to conditions where hyperfibrinolysis is observed, such as trauma [59]. This group
has previously published findings on the importance of endothelial derived endogenous
tPA in suppressing thrombus propagation [7]. Interestingly, endogenous levels of tPA
facilitate fibrinolytic activity in vivo in a process that is mechanistically coupled to clot
retraction [57].
In our previous study, we demonstrated local endogenous release of tPA induced by
bradykinin alone was not enough to produce a system increase in fibrinolytic activity [7].
Stimulation of tPA release with the beta-adrenergic agonists, isoproterenol, also does not
alter systemic tPA concentrations [60]. Similarly, in an elegant in vivo model of local
ischaemia in pig hearts, a significant increase in local venous tPA activity was observed, yet
arterial tPA activity remained unchanged [61]. However, when bradykinin infusion was
combined with inhibition of angiotensin converting enzyme (ACE) to limit metabolism
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of the vasodilator, there was a systemic spill over of tPA, as measured in the non-infused
arm [7]. In areas of vessel occlusion, it is expected that bradykinin levels would be higher
than those obtained in healthy volunteers due to reduced dilutional effects [7]. Indeed, in
patients with established heart disease on long term ACE inhibitor therapy, bradykinin
induced plasma tPA activity similar to those seen with systemic thrombolytic therapy [62].
Hrafnkelsdottir et al. demonstrated that the release from the endothelium is the important
determinant in local levels of active tPA in organs [63]. Localised pulmonary inter-arterial
thrombolysis with streptokinase was shown to be more effective than systemic thrombolysis
in reducing morbidity and mortality in patients with high risk pulmonary embolism [64].
These exciting data reveal the importance of localised fibrinolysis in dictating thrombus
propagation and persistence in vivo and warrant further investigation.
Here, we illustrate the crucial impact of shear stress on the accumulation and activity
of fibrinolytic proteins in thrombi and how this dictates their susceptibility to endogenous
fibrinolysis. It is clear that, despite the relatively low concentrations of tPA compared to
PAI-1, the activity of this enzyme is preserved within the microenvironment of the throm-
bus due to surface-mediated interactions. Thrombi formed under high shear conditions are
significantly more resistant to fibrinolysis, with higher PAI-1 content and lower tPA and
plasminogen concentrations. Fibrin structure may also play a role in this context in terms
of dampening the fibrinolytic response. These data indicate that local levels of endogenous
tPA released from the endothelium and the shear force applied to a forming thrombus in
the vasculature will likely have a powerful influence on its susceptibility to degradation.
4. Methods
4.1. Subjects and Blood Collection
All blood samples were obtained after approval of local research ethics committees, in
accordance with the Declaration of Helsinki and after obtaining written consent.
For Chandler model thrombus studies, citrated whole blood was collected from
consented healthy subjects in 0.1 volume of 0.13 M trisodium citrate.
For the Badimon studies, healthy non-smokers were enrolled. Exclusion criteria were
bleeding diathesis, the use of regular medication or any clinically significant illness. None
of the subjects received vasoactive medication during the study and all abstained from
alcohol for 24 h and from food and caffeine-containing drinks for at least six hours before
each study. Studies were carried out with subjects lying supine in a quiet, temperature-
controlled room maintained between 22 and 25 ◦C [46,65].
Based on previous studies in which the inflammatory mediator bradykinin was
administered to healthy volunteers via intrabrachial infusion to induce endogenous tPA
release from the endothelium, [7] thrombi were formed in the presence of tPA (0, 20 and
40 ng/mL Chandler Loop studies and 0, 20 and 50 ng/mL, Badimon Chamber studies).
4.2. Chandler Model Thrombi
Thrombi were formed under flow using Chandler loop method, as previously de-
scribed [32], with the exception that tPA was incorporated during thrombus formation.
Briefly, citrated whole blood (900 µL) with the addition of FITC-labelled fibrinogen
(43.5 µg/mL Kabi fibrinogen, labelled in house) ± 20 or 40 ng/mL tPA (Genentech)
was recalcified with 10.9 mM CaCl2 to give a final volume of 1.15 mL. Thrombi were
formed under rotation at 30 rpm for 30, 60 or 90 min, after which thrombi were removed
from the tubing and the remaining serum was stored for future analysis or fluorescence
measurements. Formed thrombi were washed in 0.9% (w/v) saline, before being placed
in phosphate buffered saline (10 mM phosphate, 150 mM NaCl, pH = 7.4) bathing fluid
at 37 ◦C. Samples were taken every 30 min for 4 h and diluted 1/50 in bathing buffer.
Fluorescence release was quantified in the bathing fluid (500 µL) and in serum (1 mL) using
a cytofluor multiwell plate reader (series 4000; Applied Biosystems, Framingham, MA,
USA) with an excitation wavelength of 485 nm and emission wavelength of 530 nm.
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4.3. Badimon Chamber Thrombus Formation
Thrombi were formed under defined shear rates using the Badimon Chamber [46].
In brief, blood from an antecubital vein was drawn by a pump through two cylindrical
perfusion chambers arranged in series and maintained at 37 ◦C in a water bath. Strips
of porcine aorta (Pel-Freez Biologicals, Rogers, AR, USA), from which the intima and a
thin layer of media had been removed, acted as the thrombogenic substrate. FITC-labelled
fibrinogen and tPA (0, 20 and 50 ng/mL) were administrated via a calibrated syringe-driver
into the extracorporeal circuit. Flow conditions within the first chamber simulate those
with a normal coronary artery (low shear rate, approximately 212 s−1), whilst those in the
second chamber simulate flow conditions within a mild to moderately stenosed coronary
artery (high shear rate, approximately 1690 s−1). Each study lasted for 5 min, during
which blood flow was maintained at a constant rate of 10 mL/min using a peristaltic pump
(Masterflex model 7013, Cole-Palmer Instruments, St. Neots, UK) positioned distally to
the chambers. The effluent (50.5 mL) was collected into 0.13 M trisodium citrate and kept
on ice until platelet free plasma was collected by centrifugation at 2000× g for 30 min
at 4 ◦C. Following perfusion of blood, the chambers were flushed with 0.9% saline for
1 min under the same rheological conditions. The porcine strips, with thrombi attached,
were subsequently added to the bathing fluid (0.5 mL) and fibrinolysis quantified by
fluorescence release.
4.4. Enzyme-Linked Immunosorbant Assays
ELISAs for tPA, PAI-1 and plasminogen were performed, as previously described [66].
The fibrin degradation product, D-dimer, was measured using a commercially available
kit, Asserachrom D-DI ELISA kit (Diagnostica Stago Inc., Theale, UK). Antigens were
quantified in serum from Chandler model thrombi, Badimon chamber effluent and bathing
fluid from both models. Chandler model thrombi were analysed as whole thrombi, or head
and tail sections extracted in 500 (whole thrombi or head section) and 250 µl (tail section)
extraction buffer (50 mM phosphate at pH = 7.0, 0.2 M ε-amino-N-caproic acid, 1 M NaCl
and 0.01% Tween 20), respectively.
4.5. SDS-PAGE Zymography
Model thrombi extracts and serum were analysed for tPA activity by zymography, as
previously described [67]. Briefly, proteins were separated on 10% SDS-PAGE gels. The gels
were washed in 2.5% (v/v) aqueous Triton X-100 and rinsed with distilled water. The gel
was then placed on a fibrin/agarose (0.2% Kabi fibrinogen, 0.06 NIH U/mL, 0.8% agarose
type 1; Sigma-Aldrich, Darmstadt, Germany) detector plate and incubated at 37 ◦C. After
16 h the gel was removed, and the detector plate was left to develop for 24–48 h before
being photographed.
4.6. Statistical Analysis
Rates of lysis (FU/min) and D-dimer release (µg/mL/min) for thrombi formed in both
the models were determined by best fit of the slope to a centred second-order polynomial
quadratic in GraphPad Prism 8.4 and used to calculate fold differences in lysis and D-dimer
release. Antigen levels were calculated as ng based on the concentrations obtained by
ELISA and the corresponding total volume of each fraction. Statistical significance was
determined by a one-way analysis of variance with a Tukey’s multiple comparison post-
hoc test.
Supplementary Materials: The following are available online at https://www.mdpi.com/1422-006
7/22/4/2115/s1, Figure S1: Chandler model thrombi formed at different rotation times.
Author Contributions: C.S.W. analysed data and wrote the manuscript, A.A.M. and K.M.B. per-
formed the research and analysed data, A.J.L. performed the research and proofread the manuscript,
D.E.N. and N.A.B. supervised the research and proofread the manuscript, N.J.M. analysed data and
wrote the manuscript. All authors have read and agreed to the published version of the manuscript.
Int. J. Mol. Sci. 2021, 22, 2115 11 of 13
Funding: This research was funded by British Heart Foundation PG/08/127/26517 awarded to
N.A.B. and D.E.N. C.S.W. and N.J.M. were supported by the British Heart Foundation project grants
(PG/15/82/31721 and PG/20/17/35050). D.E.N. and A.J.L. were supported by the British Heart
Foundation project grant PG/04/131/18118. D.E.N. is supported by the British Heart Foundation
(CH/09/002, RE/18/5/34216, RG/16/10/32375) and is the recipient of a Wellcome Trust Senior
Investigator Award (WT103782AIA).
Institutional Review Board Statement: The study was conducted according to the guidelines of
the Declaration of Helsinki and approved by the Institutional Research Ethics Committee of the
University of Edinburgh and University of Aberdeen.
Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.
Data Availability Statement: The data presented in this study are available on request from the
corresponding author.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Robbins, K.C.; Summaria, L.; Hsieh, B.; Shah, R.J. The peptide chains of human plasmin. Mechanism of activation of human
plasminogen to plasmin. J. Biol. Chem. 1967, 242, 2333–2342. [CrossRef]
2. Robbins, K.C.; Bernabe, P.; Arzadon, L.; Summaria, L. NH2-terminal sequences of mammalian plasminogens and plasmin
S-carboxymethyl heavy (A) and light (B) chain derivatives. A re-evaluation of the mechanism of activation of plasminogen. J.
Biol. Chem. 1973, 248, 7242–7246. [CrossRef]
3. Oliver, J.J.; Webb, D.J.; Newby, D.E. Stimulated Tissue Plasminogen Activator Release as a Marker of Endothelial Function in
Humans. Arter. Thromb. Vasc. Biol. 2005, 25, 2470–2479. [CrossRef]
4. Newby, D.E.; McLeod, A.L.; Uren, N.G.; Flint, L.; Ludlam, C.A.; Webb, D.J.; Fox, K.A.; Boon, N.A. Impaired coronary tissue
plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: Direct link between endothelial
dysfunction and atherothrombosis. Circulation 2001, 103, 1936–1941. [CrossRef] [PubMed]
5. Witherow, F.N.; Helmy, A.; Webb, D.J.; Fox, K.A.; Newby, D.E. Bradykinin contributes to the vasodilator effects of chronic
angiotensin-converting enzyme inhibition in patients with heart failure. Circulation 2001, 104, 2177–2181. [CrossRef] [PubMed]
6. Diamond, S.L.; Eskin, S.G.; McIntire, L.V. Fluid flow stimulates tissue plasminogen activator secretion by cultured human
endothelial cells. Science 1989, 243, 1483–1485. [CrossRef]
7. Lucking, A.J.; Gibson, K.R.; Paterson, E.E.; Faratian, D.; Ludlam, C.A.; Boon, N.A.; Fox, K.A.; Newby, D.E. Endogenous Tissue
Plasminogen Activator Enhances Fibrinolysis and Limits Thrombus Formation in a Clinical Model of Thrombosis. Arter. Thromb.
Vasc. Biol. 2013, 33, 1105–1111. [CrossRef]
8. Brogren, H.; Karlsson, L.; Andersson, M.; Wang, L.; Erlinge, D.; Jern, S. Platelets synthesize large amounts of active plasminogen
activator inhibitor 1. Blood 2004, 104, 3943–3948. [CrossRef] [PubMed]
9. Booth, N.A.; Simpson, A.J.; Croll, A.; Bennett, B.; MacGregor, I.R. Plasminogen activator inhibitor (PAI-1) in plasma and platelets.
Br. J. Haematol. 1988, 70, 327–333. [CrossRef]
10. Morrow, G.B.; Whyte, C.S.; Mutch, N.J. Functional plasminogen activator inhibitor 1 is retained on the activated platelet
membrane following platelet activation. Haematololgy 2019, 105, 2824–2833. [CrossRef]
11. Van Mourik, J.A.; Lawrence, D.A.; Loskutoff, D.J. Purification of an inhibitor of plasminogen activator (antiactivator) synthesized
by endothelial cells. J. Biol. Chem. 1984, 259, 14914–14921. [CrossRef]
12. Morange, P.E.; Alessi, M.C.; Verdier, M.; Casanova, D.; Magalon, G.; Juhan-Vague, I. PAI-1 Produced Ex Vivo by Human Adipose
Tissue Is Relevant to PAI-1 Blood Level. Arter. Thromb. Vasc. Biol. 1999, 19, 1361–1365. [CrossRef] [PubMed]
13. Loskutoff DJ, Samad F. The adipocyte and hemostatic balance in obesity: Studies of PAI-1. Arterioscler Thromb. Vasc. Biol. 1998, 18,
1–6. [CrossRef] [PubMed]
14. Crandall, D.L.; Quinet, E.M.; Morgan, G.A.; Busler, D.E.; McHendry-Rinde, B.; Kral, J.G. Synthesis and secretion of plasminogen
activator inhibitor-1 by human preadipocytes. J. Clin. Endocrinol. Metab. 1999, 84, 3222–3227. [CrossRef] [PubMed]
15. Cwikel, B.J.; Barouski-Miller, A.P.; Coleman, P.L.; Gelehrter, T.D. Dexamethasone induction of an inhibitor of plasminogen
activator in HTC hepatoma cells. J. Biol. Chem. 1984, 259, 6847–6851. [CrossRef]
16. Chun, T.-Y.; Pratt, J.H. Aldosterone increases plasminogen activator inhibitor-1 synthesis in rat cardiomyocytes. Mol. Cell.
Endocrinol. 2005, 239, 55–61. [CrossRef]
17. Kruithof, E.K.O. Regulation of plasminogen activator inhibitor type 1 gene expression by inflammatory mediators and statins.
Thromb. Haemost. 2008, 100, 969–975. [CrossRef]
18. Kruithof, O.E.K.; Mestries, J.C.; Gascon, M.-P.; Ythier, A. The Coagulation and Fibrinolytic Responses of Baboons after In Vivo
Thrombin Generation – Effect of Interleukin 6. Thromb. Haemost. 1997, 77, 0905–0910. [CrossRef]
19. Van der Poll, T.; Levi, M.; Buller, H.R. Fibrinolytic response to tumor necrosis factor in healthy subjects. J. Exp. Med. 1991, 174,
729–732. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 2115 12 of 13
20. Quax, P.H.; Hoogen, van den Hoogen, M.C.; Verheijen, J.H.; Padro, T.; Zeheb, R.; Gelehrter, T.D.; Van Berkel, T.J.; Kuiper, J.; Emeis,
J.J. Endotoxin induction of plasminogen activator and plasminogen activator inhibitor type 1 mRNA in rat tissues in vivo. J. Biol.
Chem. 1990, 265, 15560–15563. [CrossRef]
21. Sawdey, M.S.; Loskutoff, D.J. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue
specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J. Clin.
Investig. 1991, 88, 1346–1353. [CrossRef] [PubMed]
22. Mestries, J.C.; Kruithof, E.K.; Gascon, M.P.; Herodin, F.; Agay, D.; Ythier, A. In vivo modulation of coagulation and fibrinolysis by
recombinant glycosylated human interleukin-6 in baboons. Eur. Cytokine Netw. 1994, 5, 275–281. [PubMed]
23. Robbie, A.L.; Young, S.P.; Bennett, B.; Booth, A.N. Thrombi formed in a Chandler loop mimic human arterial thrombi in structure
and PAI-1 content and distribution. Thromb. Haemost. 1997, 77, 510–515. [CrossRef]
24. Falati, S.; Gross, P.; Merrill-Skoloff, G.; Furie, B.C.; Furie, B. Real-time in vivo imaging of platelets, tissue factor and fibrin during
arterial thrombus formation in the mouse. Nat. Med. 2002, 8, 1175–1180. [CrossRef]
25. Weisel, J.; Litvinov, R. The Biochemical and Physical Process of Fibrinolysis and Effects of Clot Structure and Stability on the Lysis
Rate. Cardiovasc. Hematol. Agents Med. Chem. 2008, 6, 161–180. [CrossRef] [PubMed]
26. Brown, A.E.X.; Litvinov, R.I.; Discher, D.E.; Purohit, P.K.; Weisel, J.W. Multiscale Mechanics of Fibrin Polymer: Gel Stretching
with Protein Unfolding and Loss of Water. Science 2009, 325, 741–744. [CrossRef]
27. Varjú, I.; Sótonyi, P.; Machovich, R.; Szabo, L.; Tenekedjiev, K.; Silva, M.M.C.G.; Longstaff, C.; Kolev, K. Hindered dissolution of
fibrin formed under mechanical stress. J. Thromb. Haemost. 2011, 9, 979–986. [CrossRef]
28. Collet, J.P.; Park, D.; Lesty, C.; Soria, J.; Soria, C.; Montalescot, G.; Weisel, J.W. Influence of fibrin network conformation and fibrin
fiber diameter on fibrinolysis speed: Dynamic and structural approaches by confocal microscopy. Arterioscler. Thromb. Vasc. Biol.
2000, 20, 1354–1361. [CrossRef]
29. Collet, J.; Allali, Y.; Lesty, C.; Tanguy, M.; Silvain, J.; Ankri, A.; Blanchet, B.; Dumaine, R.; Gianetti, J.; Payot, L.; et al. Altered
Fibrin Architecture Is Associated With Hypofibrinolysis and Premature Coronary Atherothrombosis. Arter. Thromb. Vasc. Biol.
2006, 26, 2567–2573. [CrossRef]
30. Jang, I.K.; Gold, H.K.; Ziskind, A.; Fallon, J.T.; E Holt, R.; Leinbach, R.C.; May, J.W.; Collen, D. Differential sensitivity of
erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible
explanation for resistance to coronary thrombolysis. Circulation 1989, 79, 920–928. [CrossRef]
31. Tomkins, A.J.; Schleicher, N.; Murtha, L.; Kaps, M.; Levi, C.R.; Nedelmann, M.; Spratt, N.J. Platelet rich clots are resistant to lysis
by thrombolytic therapy in a rat model of embolic stroke. Exp. Transl. Stroke Med. 2015, 7, 1–9. [CrossRef] [PubMed]
32. Mutch, N.J.; Moore, N.R.; Wang, E.; Booth, N.A. Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI. J. Thromb.
Haemost. 2003, 1, 2000–2007. [CrossRef]
33. Emeis, J.J. Regulation of the Acute Release of Tissue-type Plasminogen Activator from the Endothelium by Coagulation Activation
Products. Ann. NY Acad. Sci. 1992, 667, 249–258. [CrossRef] [PubMed]
34. Mutch, N.J.; Thomas, L.; Moore, N.R.; Lisiak, K.M.; Booth, N.A. TAFIa, PAI-1 and α2-antiplasmin: Complementary roles in
regulating lysis of thrombi and plasma clots. J. Thromb. Haemost. 2007, 5, 812–817. [CrossRef]
35. Mutch, N.J.; Koikkalainen, J.S.; Fraser, S.R.; Duthie, K.M.; Griffin, M.; Mitchell, J.; Watson, H.G.; Booth, N.A. Model thrombi
formed under flow reveal the role of factor XIII-mediated cross-linking in resistance to fibrinolysis. J. Thromb. Haemost. 2010, 8,
2017–2024. [CrossRef]
36. Fraser, S.R.; Booth, N.A.; Mutch, N.J. The antifibrinolytic function of factor XIII is exclusively expressed through alpha-antiplasmin
cross-linking. Blood 2011, 117, 6371–6374. [CrossRef]
37. Mitchell, J.L.; Lionikiene, A.S.; Fraser, S.R.; Whyte, C.S.; Booth, N.A.; Mutch, N.J. Functional factor XIII-A is exposed on the
stimulated platelet surface. Blood 2014, 124, 3982–3990. [CrossRef] [PubMed]
38. Whyte, C.S.; Swieringa, F.; Mastenbroek, T.G.; Lionikiene, A.S.; Lancé, M.D.; Van Der Meijden, P.E.J.; Heemskerk, J.W.M.; Mutch,
N.J. Plasminogen associates with phosphatidylserine-exposing platelets and contributes to thrombus lysis under flow. Blood 2015,
125, 2568–2578. [CrossRef]
39. Robbie, L.; Berry, S.; Bennett, B.; Mutch, N.; Moir, E.; Booth, N. Localization and Identification of Thrombin and Plasminogen
Activator Activities in Model Human Thrombi by in situ Zymography. Thromb. Haemost. 2002, 88, 996–1002. [CrossRef]
40. Moir, E.; Booth, N.A.; Bennett, B.; Robbie, L.A. Polymorphonuclear leucocytes mediate endogenous thrombus lysis via a
u-PA-dependent mechanism. Br. J. Haematol. 2001, 113, 72–80. [CrossRef]
41. Chernysh, I.N.; Nagaswami, C.; Kosolapova, S.; Peshkova, A.D.; Cuker, A.; Cines, D.B.; Cambor, C.L.; Litvinov, R.I.; Weisel,
J.W. The distinctive structure and composition of arterial and venous thrombi and pulmonary emboli. Sci. Rep. 2020, 10, 1–12.
[CrossRef] [PubMed]
42. Whyte, C.S.; Morrow, G.B.; Baik, N.; Booth, N.A.; Jalal, M.M.; Parmer, R.J.; Miles, L.A.; Mutch, N.J. Exposure of plasminogen and
a novel plasminogen receptor, Plg-RKT, on activated human and murine platelets. Blood 2021, 137, 248–257. [CrossRef] [PubMed]
43. Zhu, Y.; Carmeliet, P.; Fay, W.P. Plasminogen Activator Inhibitor-1 Is a Major Determinant of Arterial Thrombolysis Resistance.
Circulation 1999, 99, 3050–3055. [CrossRef]
44. A Robbie, L.; Bennett, B.; Croll, A.M.; Brown, P.A.J.; A Booth, N. Proteins of the Fibrinolytic System in Human Thrombi. Thromb.
Haemost. 1996, 75, 127–133. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 2115 13 of 13
45. Booth, N.A.; Robbie, L.A.; Croll, A.M.; Bennett, B. Lysis of Platelet-rich Thrombi: The Role of PAI?1. Ann. NY. Acad. Sci. 1992, 667,
70–80. [CrossRef] [PubMed]
46. Lucking, A.J.; Chelliah, R.; Trotman, A.D.; Connolly, T.M.; Feuerstein, G.Z.; Fox, K.A.; Boon, N.A.; Badimon, J.J.; Newby, D.E.
Characterisation and reproducibility of a human ex vivo model of thrombosis. Thromb. Res. 2010, 126, 431–435. [CrossRef]
[PubMed]
47. Gersh, K.C.; Edmondson, K.E.; Weisel, J.W. Flow rate and fibrin fiber alignment. J. Thromb. Haemost. 2010, 8, 2826–2828. [CrossRef]
48. Campbell, R.A.; Aleman, M.M.; Gray, L.D.; Falvo, M.R.; Wolberg, A.S. Flow profoundly influences fibrin network structure:
Implications for fibrin formation and clot stability in haemostasis. Thromb. Haemost. 2010, 104, 1281–1284. [CrossRef] [PubMed]
49. Neeves, K.; Illing, D.; Diamond, S. Thrombin Flux and Wall Shear Rate Regulate Fibrin Fiber Deposition State during Polymeriza-
tion under Flow. Biophys. J. 2010, 98, 1344–1352. [CrossRef]
50. Whittaker, P.; Przyklenk, K. Fibrin architecture in clots: A quantitative polarized light microscopy analysis. Blood Cells Mol. Dis.
2009, 42, 51–56. [CrossRef]
51. Loyau, S.; Ho-Tin-Noé, B.; Bourrienne, M.-C.; Boulaftali, Y.; Jandrot-Perrus, M. Microfluidic Modeling of Thrombolysis. Arter.
Thromb. Vasc. Biol. 2018, 38, 2626–2637. [CrossRef] [PubMed]
52. Stalker, T.J.; Traxler, E.A.; Wu, J.; Wannemacher, K.M.; Cermignano, S.L.; Voronov, R.; Diamond, S.L.; Brass, L.F. Hierarchical
organization in the hemostatic response and its relationship to the platelet-signaling network. Blood 2013, 121, 1875–1885.
[CrossRef] [PubMed]
53. Welsh, J.D.; Stalker, T.J.; Voronov, R.; Muthard, R.W.; Tomaiuolo, M.; Diamond, S.L.; Brass, L.F. A systems approach to hemostasis:
1. The interdependence of thrombus architecture and agonist movements in the gaps between platelets. Blood 2014, 124, 1808–1815.
[CrossRef] [PubMed]
54. Stalker, T.J.; Welsh, J.D.; Tomaiuolo, M.; Wu, J.; Colace, T.V.; Diamond, S.L.; Brass, L.F. A systems approach to hemostasis:
3. Thrombus consolidation regulates intrathrombus solute transport and local thrombin activity. Blood 2014, 124, 1824–1831.
[CrossRef] [PubMed]
55. Miles, L.A.; Castellino, F.J.; Gong, Y. Critical role for conversion of glu-plasminogen to Lys-plasminogen for optimal stimulation
of plasminogen activation on cell surfaces. Trends. Cardiovasc. Med. 2003, 13, 21–30. [CrossRef]
56. Dejouvencel, T.; Doeuvre, L.; Lacroix, R.; Plawinski, L.; Dignat-George, F.; Lijnen, H.R.; Anglés-Cano, E. Fibrinolytic cross-talk: A
new mechanism for plasmin formation. Blood 2010, 115, 2048–2056. [CrossRef]
57. Samson, A.L.; Alwis, I.; MacLean, J.A.A.; Priyananda, P.; Hawkett, B.; Schoenwaelder, S.M.; Jackson, S.P. Endogenous fibrinolysis
facilitates clot retraction in vivo. Blood 2017, 130, 2453–2462. [CrossRef]
58. Brzoska, T.; Tanaka-Murakami, A.; Suzuki, Y.; Sano, H.; Kanayama, N.; Urano, T. Endogenously Generated Plasmin at the
Vascular Wall Injury Site Amplifies Lysine Binding Site-Dependent Plasminogen Accumulation in Microthrombi. PLOS ONE
2015, 10, e0122196. [CrossRef]
59. Li, R.; Elmongy, H.; Sims, C.; Diamond, S.L. Ex vivo recapitulation of trauma-induced coagulopathy and preliminary assessment
of trauma patient platelet function under flow using microfluidic technology. J. Trauma Acute Care Surg. 2016, 80, 440–449.
[CrossRef]
60. Stein, C.; Brown, N.; Vaughan, E.D.; Lang, C.C.; Wood, A.J. Regulation of local tissue-type plasminogen activator release by
endothelium-dependent and endothelium-independent agonists in human vasculature. J. Am. Coll. Cardiol. 1998, 32, 117–122.
[CrossRef]
61. Aspelin, T.; Eriksen, M.; Lindgaard, A.-K.; Lyberg, T.; Ilebekk, A. Cardiac fibrinolytic capacity is markedly increased after brief
periods of local myocardial ischemia, but declines following successive periods in anesthetized pigs. J. Thromb. Haemost. 2005, 3,
1947–1954. [CrossRef]
62. Witherow, F.N.; Dawson, P.; A Ludlam, C.; Fox, K.; Newby, D. Marked bradykinin-induced tissue plasminogen activator release
in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapy. J. Am. Coll. Cardiol.
2002, 40, 961–966. [CrossRef]
63. Hrafnkelsdottir, T.; Gudnason, T.; Wall, U.; Jern, C.; Jern, S. Regulation of local availability of active tissue-type plasminogen
activator in vivo in man. J. Thromb. Haemost. 2004, 2, 1960–1968. [CrossRef] [PubMed]
64. Macovei, L.; Presura, R.M.; Georgescu, C.A. Systemic or local thrombolysis in high-risk pulmonary embolism. Cardiol. J. 2015, 22,
467–474. [CrossRef]
65. Lucking, A.J.; Visvanathan, A.; Philippou, H.; Fraser, S.; Grant, P.J.; Connolly, T.M.; Gardell, S.J.; Feuerstein, G.Z.; Fox, K.A.A.;
Booth, N.A.; et al. Effect of the small molecule plasminogen activator inhibitor-1 (PAI-1) inhibitor, PAI-749, in clinical models of
fibrinolysis. J. Thromb. Haemost. 2010, 8, 1333–1339. [CrossRef] [PubMed]
66. Robbie, L.A.; Booth, N.A.; Brown, P.A.; Bennett, B. Inhibitors of Fibrinolysis Are Elevated in Atherosclerotic Plaque. Arter. Thromb.
Vasc. Biol. 1996, 16, 539–545. [CrossRef] [PubMed]
67. Moir, E.; Robbie, L.A.; Bennett, B.; Booth, N.A. Polymorphonuclear Leucocytes Have Two Opposing Roles in Fibrinolysis. Thromb.
Haemost. 2002, 87, 1006–1010. [CrossRef]
